Solventum
SOLV
$89.57
+1.08%
Solventum Corporation is a healthcare company that develops, manufactures, and commercializes solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which provides wound therapy, surgical supplies, and medical tapes; Dental Solutions, offering orthodontic and restorative products; and Health Information Systems, providing software for physician documentation and coding automation. As a spin-off from 3M, Solventum operates as a diversified healthcare technology player, competing with both medical device and health IT firms. The current investor narrative centers on the company's post-spin transformation, with recent quarterly results showing revenue decline but improved profitability, and the stock has rallied strongly over the past year as management executes on cost synergies and debt reduction.…
SOLV
Solventum
$89.57
Investment Opinion: Should I buy SOLV Today?
Based on the analysis, SOLV is rated a 'Buy' with a thesis that the market is undervaluing the company's earnings power and post-spin transformation. The consensus rating is 'buy' with an average target of $93.92, implying ~4.9% upside, but the low PE and high margins suggest potential for re-rating if revenue stabilizes.
Sign up to view all
SOLV 12-Month Price Forecast
The AI assessment is cautiously bullish, given the low valuation and high profitability, but tempered by revenue decline and negative FCF. The stock's momentum and analyst upgrades support a positive outlook, but the fundamental weakness in top-line growth is a concern. If revenue stabilizes and FCF turns positive, the stance would be upgraded to high confidence. Conversely, if revenue decline accelerates, the stance would be downgraded to neutral or bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Solventum's 12-month outlook, with a consensus price target around $93.92 and implied upside of +4.9% versus the current price.
Average Target
$93.92
0 analysts
Implied Upside
+4.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $113
Analyst target range
The target range of $70 to $113 indicates significant uncertainty about Solventum's future, with a wide spread of $43. The high target of $113 likely assumes successful execution of the company's growth strategy, including margin expansion and new product launches, while the low target of $70 may reflect concerns about continued revenue decline and competitive pressures. Recent ratings actions have been positive, with KeyBanc upgrading from Sector Weight to Overweight in January 2026 and Mizuho upgrading from Neutral to Outperform, while BTIG upgraded from Neutral to Buy in December 2025. This pattern of upgrades suggests improving sentiment among analysts, which could support the stock's momentum.
Drowning in data?
Find the real signal!
Bulls vs Bears: SOLV Investment Factors
Solventum presents a mixed picture: strong price momentum, low valuation multiples, and improving analyst sentiment contrast with persistent revenue decline, negative free cash flow, and high leverage. The bull case rests on successful execution of cost synergies and debt reduction, while the bear case hinges on continued top-line contraction and margin erosion. Currently, the bull side has slightly stronger evidence given the stock's proximity to its 52-week high and the series of analyst upgrades, but the fundamental weakness in revenue growth remains the key tension. The single most important factor is whether management can stabilize revenue growth while expanding margins; if revenue turns positive, the stock could re-rate higher, but if decline accelerates, the low PE could become a value trap.
Bullish
- Strong price momentum near 52-week high: SOLV trades at $89.57, just 0.5% below its 52-week high of $90.00, with a 1-year gain of +24.4% and a 6-month gain of +22.8%. This reflects robust investor confidence and a successful post-spin transformation narrative.
- Attractive valuation with low PE: The trailing PE is 8.86x and forward PE is 12.40x, which are low for a healthcare technology company. The PEG ratio of 0.04 suggests the stock is undervalued relative to its earnings growth potential, though this is distorted by the low trailing PE.
- Analyst upgrades and buy consensus: The consensus rating is 'buy' with a mean score of 2.2, and recent upgrades from KeyBanc, Mizuho, and BTIG indicate improving sentiment. The average analyst target of $93.92 implies ~4.9% upside from the current price.
- High profitability metrics: Net margin is 18.7% and operating margin is 26.2%, reflecting strong cost control and operational efficiency. ROE is 30.8%, indicating effective use of shareholder equity.
Bearish
- Revenue decline persists: Q4 2025 revenue fell 3.7% YoY to $1,998 million, and quarterly revenue has declined from $2,076 million in Q1 2025. This indicates a contraction trend, driven by pricing pressure in MedSurg.
- Negative free cash flow: TTM free cash flow is -$10 million, which is concerning for a company with high debt. This limits financial flexibility and could constrain future investments or dividend payments.
- High debt levels: Debt-to-equity is 0.997, near 1:1, and interest expense was $51 million in Q4 2025. High leverage increases financial risk, especially if earnings decline further.
- Gross margin compression: Gross margin fell from 53.9% in Q4 2024 to 49.3% in Q4 2025, a 460 basis point decline. This suggests cost pressures or pricing concessions that could erode profitability.
SOLV Technical Analysis
Solventum's stock is in a strong uptrend, with a 1-year price change of +24.4% and a 6-month change of +22.8%. The current price of $89.57 sits near the top of its 52-week range, at 99.5% of the high of $90.00, indicating robust momentum and investor confidence. The stock has recovered from a 52-week low of $62.38, representing a 43.6% gain from that level, and is trading just below its all-time high, suggesting a breakout attempt is underway.
Beta
0.67
0.67x market volatility
Max Drawdown
-27.5%
Largest decline past year
52-Week Range
$62-$90
Price range past year
Annual Return
+24.4%
Cumulative gain past year
| Period | SOLV Return | S&P 500 |
|---|---|---|
| 1m | +15.4% | +3.6% |
| 3m | +16.6% | +2.7% |
| 6m | +22.8% | +11.4% |
| 1y | +24.4% | +18.7% |
| ytd | +13.4% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SOLV Fundamental Analysis
Solventum's revenue has been declining, with the most recent quarter (Q4 2025) showing revenue of $1,998 million, a -3.7% YoY decline. Over the past year, quarterly revenue has ranged from $2,076 million in Q1 2025 to $1,998 million in Q4 2025, indicating a gradual contraction. The company's growth is being dragged by its MedSurg segment, which faces pricing pressure, while Health Information Systems shows resilience. Despite the revenue decline, the company has maintained a gross margin of 49.3% in Q4 2025, down from 53.9% in Q4 2024, reflecting cost pressures.
Quarterly Revenue
$2.0B
2025-12
Revenue YoY Growth
-3.7%
YoY Comparison
Gross Margin
49.3%
Latest Quarter
Free Cash Flow
$-10000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SOLV Overvalued?
Given that Solventum has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 8.86x, while the forward PE is 12.40x, indicating that the market expects earnings to decline in the coming year. The gap between trailing and forward PE suggests that the market is pricing in lower future earnings, possibly due to margin compression or higher interest expenses. The PEG ratio of 0.04 is extremely low, but this is distorted by the high growth rate implied by the low trailing PE.
PE
8.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant: Solventum carries a debt-to-equity ratio of 0.997, near 1:1, and interest expense of $51 million in Q4 2025, which consumes a large portion of operating income. The company's free cash flow is negative at -$10 million TTM, limiting its ability to service debt or invest in growth. Revenue has declined for four consecutive quarters, with Q4 2025 down 3.7% YoY, and gross margin has compressed from 53.9% to 49.3% over the same period, indicating cost pressures that could further erode profitability. The current ratio of 1.23 provides some liquidity cushion, but the negative FCF and high leverage make the financial position fragile if earnings deteriorate further.
